Vinod Vathipadiekal
Overview
Explore the profile of Vinod Vathipadiekal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
790
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
LaFargue C, Amero P, Noh K, Mangala L, Wen Y, Bayraktar E, et al.
Nat Commun
. 2023 Apr;
14(1):2407.
PMID: 37100807
Antiangiogenic treatment targeting the vascular endothelial growth factor (VEGF) pathway is a powerful tool to combat tumor growth and progression; however, drug resistance frequently emerges. We identify CD5L (CD5 antigen-like...
2.
Byrne M, Vathipadiekal V, Apponi L, Iwamoto N, Kandasamy P, Longo K, et al.
Transl Vis Sci Technol
. 2021 Jan;
10(1):23.
PMID: 33510962
Purpose: Antisense oligonucleotides have been under investigation as potential therapeutics for many diseases, including inherited retinal diseases. Chemical modifications, such as chiral phosphorothioate (PS) backbone modification, are often used to...
3.
Vathipadiekal V, Farrell J, Wang S, Edward H, Shappell H, Al-Rubaish A, et al.
Am J Hematol
. 2016 Aug;
91(11):1118-1122.
PMID: 27501013
Fetal hemoglobin (HbF) levels are higher in the Arab-Indian (AI) β-globin gene haplotype of sickle cell anemia compared with African-origin haplotypes. To study genetic elements that effect HbF expression in...
4.
Sosulski A, Horn H, Zhang L, Coletti C, Vathipadiekal V, Castro C, et al.
PLoS One
. 2016 Jun;
11(6):e0156595.
PMID: 27253518
CD44 is a transmembrane hyaluronic acid receptor gene that encodes over 100 different tissue-specific protein isoforms. The most ubiquitous, CD44 standard, has been used as a cancer stem cell marker...
5.
Vathipadiekal V, Alsultan A, Baltrusaitis K, Farrell J, Al-Rubaish A, Al-Muhanna F, et al.
Am J Hematol
. 2016 May;
91(6):E308-11.
PMID: 27185208
No abstract available.
6.
Pepin D, Sosulski A, Zhang L, Wang D, Vathipadiekal V, Hendren K, et al.
Proc Natl Acad Sci U S A
. 2015 Jul;
112(32):E4418-27.
PMID: 26216943
To improve ovarian cancer patient survival, effective treatments addressing chemoresistant recurrences are particularly needed. Mullerian inhibiting substance (MIS) has been shown to inhibit the growth of a stem-like population of...
7.
Vathipadiekal V, Wang V, Wei W, Waldron L, Drapkin R, Gillette M, et al.
Clin Cancer Res
. 2015 May;
21(21):4960-9.
PMID: 25944803
Purpose: To generate a comprehensive "Secretome" of proteins potentially found in the blood and derive a virtual Affymetrix array. To validate the utility of this database for the discovery of...
8.
Tyekucheva S, Martin N, Stack E, Wei W, Vathipadiekal V, Waldron L, et al.
J Mol Diagn
. 2015 May;
17(4):374-81.
PMID: 25937617
Archival formalin-fixed, paraffin-embedded (FFPE) tissue specimens represent a readily available but largely untapped resource for gene expression profiling-based biomarker discovery. Several technologies have been proposed to cope with the bias...
9.
Farley J, Brady W, Vathipadiekal V, Lankes H, Coleman R, Morgan M, et al.
Lancet Oncol
. 2012 Dec;
14(2):134-40.
PMID: 23261356
Background: Low-grade serous carcinoma of the ovary is chemoresistant but mutations in the MAPK pathway could be targeted to control tumour growth. We therefore assessed the safety and activity of...
10.
May T, Shoni M, Crum C, Xian W, Vathipadiekal V, Birrer M, et al.
Gynecol Oncol
. 2012 Dec;
128(3):488-92.
PMID: 23253401
Objective: Mullerian low grade serous carcinoma (LGSC) and high grade serous carcinoma (HGSC) have distinct molecular profiles, clinical behavior and treatment response. Our objective was to study the biological profiles...